Brandon Capital leads $14m investment to develop new cancer drug
Otago University spinout Amaroq is first deal under deep tech incubator.
Nicola Shepheard
Thu, 08 Jul 2021
Hot Topic
NBR Focus: The Accountants 2024
A new spinout from the University of Otago has secured $14 million in backing to help develop a new kind of targeted cancer drug in the emerging field of RNA therapy.
The Amaroq Therapeutics team, led by chief scientific officer and founder Dr Sarah Diermeier, are pioneers in exploring the use
Want to read more? It's easy.
Choose your best value subscription option
Individual
Group membership
NBR Marketplace
NZ Aviation News
Yearly Premium Online Subscription
NZ$499.00 / yearly
Monthly Premium Online Subscription
NZ$44.95 / monthly
Smartphone Only Subscription
NZ$24.95 / monthly
Premium Group Membership 10 Users
NZ$350+GST / monthly
$35 per user - Pay by monthly credit card debitPremium Group Membership 20 Users
NZ$600+GST / monthly
$30 per user - Pay by monthly credit card debitPremium Group Membership 50 Users
NZ$1250+GST / monthly
$25 per user - Pay by monthly credit card debitPremium Group Membership 100 Users
NZ$1875+GST / monthly
$18.75 per user - Pay by monthly credit card debitYearly Premium Online Subscription + NBR Marketplace
NZ$499.00 / yearly
Aviation News - Monthly
NZ$14.95 / monthly
Already have an account? Login
Nicola Shepheard
Thu, 08 Jul 2021
Contact the Writer: nicola@nbr.co.nz
News tip? Question? Typo? Let us know: editor@nbr.co.nz
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Brandon Capital leads $14m investment to develop new cancer drug
Business,
88058